Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.
Protopic and Elidel, two treatments for eczema approved in 2000 and 2001, have now been found to cause cancer in three different animal species.
A number of clinical symptoms and signs are included under the broad group Rosacea. Facial flushing, the appearance of broken blood vessels and persistent redness of the face, eruption of inflamed spots & pimples, on the face and thickening of the sebaceous glands of the nose, with swelling & congestion in that area.
Transplant researchers at the University of Pittsburgh's Thomas E. Starzl Transplantation Institute have dramatically improved intestinal transplant graft survival, and reduced rejection and infection rates by successfully using a novel immunosuppression minimization protocol, thus improving patients' overall quality of life and avoiding the use of several anti-rejection drugs, which can cause serious infections and major complications.
Patients who suffer a loss of cognitive and motor function as a result of stem cell transplantation for severe blood disorders are likely to see those functions return to previous levels after one year, according to a new study in the November 15, 2004, issue of Blood, the official journal of the American Society of Hematology.
“The big advantage [of this combination of drugs] is that the incidence of rejection is significantly decreased,” he says. “These results could change the standard of care for liver transplant recipients.”
Patients with vitiligo, a skin disorder characterized by patches of white, or de-pigmented skin, had better repigmentation of these patches when they were treated with a combination of laser therapy and tacrolimus ointment than patients treated with laser therapy alone
A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.
A drug duo appears to be a safe and effective way to prevent a serious condition called graft-versus-host-disease (GVHD) in youngsters undergoing a stem cell transplant